A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia
Status:
Completed
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants
with schizophrenia.
Also primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with
schizophrenia as measured by cognitive function and neurophysiological biomarkers.
The secondary purpose of this study is to evaluate the pharmacokinetics of ASP6981 in
participants with schizophrenia.